190 related articles for article (PubMed ID: 21039844)
1. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Liu YL; Yang YM; Xu H; Dong XS
J Gastroenterol Hepatol; 2010 Nov; 25(11):1800-5. PubMed ID: 21039844
[TBL] [Abstract][Full Text] [Related]
2. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway.
Liu YL; Jiang SX; Yang YM; Xu H; Liu JL; Wang XS
Cell Biochem Biophys; 2012 Jan; 62(1):229-35. PubMed ID: 21928107
[TBL] [Abstract][Full Text] [Related]
3. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas.
Liu Y; Yang Y; Xu H; Dong X
Diagn Mol Pathol; 2010 Dec; 19(4):194-200. PubMed ID: 21052002
[TBL] [Abstract][Full Text] [Related]
4. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma.
Yang DD; Cui BB; Sun LY; Zheng HQ; Huang Q; Tong JX; Zhang QF
Cell Biochem Biophys; 2011 Dec; 61(3):703-10. PubMed ID: 21735131
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer.
Hu J; Liu YL; Piao SL; Yang DD; Yang YM; Cai L
Lung Cancer; 2012 Sep; 77(3):593-9. PubMed ID: 22717106
[TBL] [Abstract][Full Text] [Related]
6. ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma.
Zhuang YJ; Liao ZW; Yu HW; Song XL; Liu Y; Shi XY; Lin XD; Zhou TC
Cancer Biol Ther; 2015; 16(1):88-96. PubMed ID: 25482932
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma.
Piao S; Ma J; Wang W; Liu Y; Zhang M; Chen H; Guo F; Zhang B; Guo F
Oral Oncol; 2013 Aug; 49(8):796-801. PubMed ID: 23664741
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma.
Dai W; Yao Y; Zhou Q; Sun CF
PLoS One; 2014; 9(1):e87148. PubMed ID: 24466336
[TBL] [Abstract][Full Text] [Related]
9. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas.
Silva J; García JM; Peña C; García V; Domínguez G; Suárez D; Camacho FI; Espinosa R; Provencio M; España P; Bonilla F
Clin Cancer Res; 2006 Dec; 12(23):6929-36. PubMed ID: 17145810
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer.
Liu YL; Yang YM; Xu H; Dong XS
J Surg Oncol; 2011 Mar; 103(3):283-9. PubMed ID: 21337558
[TBL] [Abstract][Full Text] [Related]
11. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells.
Kim D; Hong A; Park HI; Shin WH; Yoo L; Jeon SJ; Chung KC
J Cell Physiol; 2017 Dec; 232(12):3664-3676. PubMed ID: 28160502
[TBL] [Abstract][Full Text] [Related]
12. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins.
Kim JH; Yoon SY; Kim CN; Joo JH; Moon SK; Choe IS; Choe YK; Kim JW
Cancer Lett; 2004 Jan; 203(2):217-24. PubMed ID: 14732230
[TBL] [Abstract][Full Text] [Related]
13. The deubiquitinating enzyme activity of USP22 is necessary for regulating HeLa cell growth.
Liu YL; Zheng J; Tang LJ; Han W; Wang JM; Liu DW; Tian QB
Gene; 2015 Nov; 572(1):49-56. PubMed ID: 26143114
[TBL] [Abstract][Full Text] [Related]
14. Knock-down of USP22 by small interfering RNA interference inhibits HepG2 cell proliferation and induces cell cycle arrest.
Ling SB; Sun DG; Tang B; Guo C; Zhang Y; Liang R; Wang LM
Cell Mol Biol (Noisy-le-grand); 2012 Dec; 58 Suppl():OL1803-8. PubMed ID: 23217440
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer.
Ning J; Zhang J; Liu W; Lang Y; Xue Y; Xu S
Eur J Histochem; 2012 Nov; 56(4):e46. PubMed ID: 23361242
[TBL] [Abstract][Full Text] [Related]
16. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.
Ning Z; Wang A; Liang J; Xie Y; Liu J; Feng L; Yan Q; Wang Z
Int J Oncol; 2014 Oct; 45(4):1594-608. PubMed ID: 24993031
[TBL] [Abstract][Full Text] [Related]
17. USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 protein.
Ma Y; Fu HL; Wang Z; Huang H; Ni J; Song J; Xia Y; Jin WL; Cui DX
Oncotarget; 2017 May; 8(20):33329-33342. PubMed ID: 28415621
[TBL] [Abstract][Full Text] [Related]
18. Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma.
Wang Z; Zhu L; Guo T; Wang Y; Yang J
Hum Pathol; 2015 Jul; 46(7):1006-14. PubMed ID: 25971547
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer.
Zhang Y; Yao L; Zhang X; Ji H; Wang L; Sun S; Pang D
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1245-53. PubMed ID: 21691749
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression.
Sun T; Zhang K; Li W; Liu Y; Pangeni RP; Li A; Arvanitis L; Raz DJ
Cell Commun Signal; 2022 Sep; 20(1):147. PubMed ID: 36123698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
